{
    "nctId": "NCT05255523",
    "briefTitle": "Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer",
    "officialTitle": "A Single Arm\uff0cMulticenter\uff0cReal-world Observational Study of Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Incidence of first progression with brain metastases",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. age:18-75 years old, female;\n2. HER2 positive advanced breast cancer diagnosed by pathology, cytology or radiology, including inoperable breast cancer with stage IV, or recurrent/metastatic breast cancer.HER-2 positivity was confirmed by histopathological test: immunohistochemistry(IHC) results of 3 + or in situ hybridization (ISH) results of amplification of HER2;\n3. Disease progression occurs after treatment with trastuzumab (stopping the drug for more than 12 months) or newly diagnosed IV stage breast cancer patients;\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n5. Life expectancy greater than or equal to 6 months;\n6. The main organs function well, and the inspection indicators meet the following requirements:\n\n1) For results of blood routine test HB\u226590g/L; ANC\u22651.5\u00d7109/L; PLT\u226590\u00d7109/L; 2) For results of blood biochemical test ALT and AST\u22642\u00d7ULN, but\u22645\u00d7ULN if the transferanse elevation is due to liver metastases\uff1b TBIL\u22641.5\u00d7ULN\uff1b Serum creatinine \u22641.5\u00d7ULN; 7. The researchers believed that the subjects were preference to benefit; 8. Participants were willing to join in this study, and written informed consent.\n\nExclusion Criteria:\n\n1. Patients with brain metastases by CT or MRI;\n2. More factors affecting of oral drugs (gastrointestinal surgery history, inability to swallow, chronic diarrhea, intestinal obstruction);\n3. Study drug and excipient allergy;\n4. History of psychiatric drugs abuse and can't quit or patients with mental disorders;\n5. Pregnant or lactating female patients;\n6. Less than 4 weeks from the last clinical trial;\n7. The researchers think inappropriate.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}